€29.00
0.00% yesterday
Xetra, Aug 11, 05:36 pm CET
ISIN
DE000A2P4LJ5
Symbol
PSG
Index

Pharmasgp Holding Stock price

€29.00
+0.40 1.40% 1M
+2.20 8.21% 6M
+4.00 16.00% YTD
+8.40 40.78% 1Y
+4.10 16.47% 3Y
-2.85 8.95% 5Y
-5.50 15.94% 10Y
-5.50 15.94% 20Y
Xetra, Closing price Mon, Aug 11 2025
+0.00 0.00%
ISIN
DE000A2P4LJ5
Symbol
PSG
Index
Industry

Key metrics

Basic
Market capitalization
€348.0m
Enterprise Value
€385.0m
Net debt
€37.0m
Cash
€29.3m
Shares outstanding
12.0m
Valuation (TTM | estimate)
P/E
23.6 | 18.2
P/S
3.8 | 3.0
EV/Sales
4.2 | 3.3
EV/FCF
negative
P/B
9.5
Dividends
DPS
€1.36
Yield 1Y | 5Y
4.7% | 1.9%
Growth 1Y | 5Y
177.6% | -
Payout 1Y | 3Y
35.8% | 28.8%
Increased
3 Years
Financials (TTM | estimate)
Revenue
€91.8m | €115.5m
EBITDA
€27.5m | €36.6m
EBIT
€20.4m | €31.3m
Net Income
€14.2m | €19.1m
Free Cash Flow
€-2.6m
Growth (TTM | estimate)
Revenue
-14.4% | 14.2%
EBITDA
-23.0% | 7.5%
EBIT
-22.4% | 27.1%
Net Income
-21.5% | 16.3%
Free Cash Flow
-110.0%
Margin (TTM | estimate)
Gross
90.7%
EBITDA
29.9% | 31.7%
EBIT
22.2%
Net
15.5% | 16.5%
Free Cash Flow
-2.9%
Financial Health
Equity Ratio
30.3%
Return on Equity
41.3%
ROCE
21.3%
ROIC
20.4%
Debt/Equity
1.8
More
EPS
€1.2
FCF per Share
€-0.2
Short interest
-
Employees
89
Rev per Employee
€1.1m
Show more

Is Pharmasgp Holding a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Pharmasgp Holding Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Pharmasgp Holding forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Pharmasgp Holding forecast:

Buy
83%
Hold
17%

Financial data from Pharmasgp Holding

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
92 92
14% 14%
100%
- Direct Costs 8.57 8.57
12% 12%
9%
83 83
15% 15%
91%
- Selling and Administrative Expenses 48 48
11% 11%
52%
- Research and Development Expense - -
-
-
27 27
23% 23%
30%
- Depreciation and Amortization 7.09 7.09
24% 24%
8%
EBIT (Operating Income) EBIT 20 20
22% 22%
22%
Net Profit 14 14
21% 21%
15%

In millions EUR.

Don't miss a Thing! We will send you all news about Pharmasgp Holding directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

PharmaSGP Holding SE engages in the manufacture of non-chemical, over-the-counter pharmaceutical products. Its product brands include RubaXX, Restaxil, FULMINAN, DESEO, Neradin, and TAUMEA. The company is headquartered in Gräfelfing, Germany.

Head office Germany
CEO Peter Gerckens
Employees 89
Founded 2012
Website pharmasgp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today